News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results